

<https://helda.helsinki.fi>

Cancer Incidence and Mortality in 260,000 Nordic Twins With 30,000 Prospective Cancers

Skytté, Axel

2019-04

Skytté , A , Harris , J R , Czene , K , Mucci , L , Adami , H-O , Christensen , K , Hjelmborg , J , Holm , N V , Nilsen , T S , Kaprio , J & Pukkala , E 2019 , ' Cancer Incidence and Mortality in 260,000 Nordic Twins With 30,000 Prospective Cancers ' , Twin Research and Human Genetics , vol. 22 , no. 2 , pp. 99-107 . <https://doi.org/10.1017/thg.2019.10>

<http://hdl.handle.net/10138/311509>

<https://doi.org/10.1017/thg.2019.10>

cc_by_nc_nd

acceptedVersion

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.

Cancer incidence and mortality in 260,000 Nordic twins with 30,000 prospective cancers

Axel Skytthe^{1,2}, Jennifer R. Harris³, Kamila Czene⁴, Lorelei Mucci⁵, Hans-Olov Adami^{4,6}, Kaare Christensen^{1,2}, Jacob Hjelmberg^{1,2}, Niels V. Holm^{1,7}, Thomas S. Nilsen⁸, Jaakko Kaprio^{9,10}, Eero Pukkala^{11,12}

Author affiliations:

¹Danish Twin Registry, Institute of Public Health, University of Southern Denmark

²Department of Epidemiology and Biostatistics, Institute of Public Health, University of Southern Denmark

³Division of Health Data and Digitalisation, Norwegian Institute of Public Health, Oslo, Norway

⁴Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

⁵Department of Epidemiology, Harvard School of Public Health, Boston, USA

⁶Clinical Effectiveness Research Group, Institute of Health and Society, University of Oslo, Oslo, Norway

⁷Department of Oncology, Odense University Hospital, Denmark

⁸Department of Health Studies, Norwegian Institute of Public Health, Oslo, Norway

⁹Department of Public Health, University of Helsinki, Finland

¹⁰Institute for Molecular Medicine FIMM, University of Helsinki, Finland

¹¹Faculty of Social Sciences, University of Tampere, Finland

¹²Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research, Helsinki, Finland

Address for correspondence:

Jacob Hjelmberg, Department of Epidemiology and Biostatistics, Institute of Public Health, University of Southern Denmark, J.B. Winsløvs Vej 9, DK-5000 Odense C, Denmark.

Key words: Twins; cancer incidence; cohort study; record linkage; selection

Word count:

Abstract: 253

Text: 4,087

Abstract

Introduction: The Nordic countries have comprehensive, population-based health and medical registries linkable on individually unique personal identity codes, enabling complete long-term follow-up. The aims of this study were to describe the NorTwinCan cohort established in 2010 and assess whether the cancer mortality and incidence rates among Nordic twins are similar to those in the general population.

Methods: We analysed approximately 260,000 same-sexed twins in the nationwide twin registers in Denmark, Finland, Norway, and Sweden. Cancer incidence was determined using follow up through the national cancer registries. We estimated standardize incidence (SIR) and mortality (SMR) ratios with 95% confidence intervals (CI) across country, age, period, follow-up time, sex and zygosity.

Results: More than 30,000 malignant neoplasms have occurred among the twins through 2010. Mortality rates among twins were slightly lower than in the general population (SMR 0.96; CI 95% 0.95-0.97) but depends on information about zygosity. Twins have slightly lower cancer incidence rates than the general population, with SIRs of 0.97; (95% CI 0.96-0.99) in men and 0.96; (95% CI 0.94-0.97) in women. Testicular cancer occurs more often among male twins than singletons (SIR 1.15; 95% CI 1.02-1.30), while cancers of the kidney, (SIR 0.82; 95% CI 0.76-0.89) lung (SIR 0.89; 95% CI 0.85-0.92), and colon (SIR 0.90; 95% CI 0.87-0.94) occur less often in twins than in the background population.

Conclusion: Our findings indicate that the risk of cancer among twins is so similar to the general population that cancer risk factors and estimates of heritability derived from the Nordic twin registers are generalizable to the background populations.

Introduction

Genetic and environmental factors contribute to the aetiology of cancer. Joint estimates of the heritability of the most common cancers based on the large twin cohorts in Denmark, Finland and Sweden were first published in 2000 (Lichtenstein et al. 2000). We expanded this analysis with the addition of data from Norway, extended the follow-up time, improved statistical methodology and tripled the number of twins with cancer. Hence, a sufficient number of cases had occurred to provide more accurate estimates for common cancers and reliable estimates for less common cancers (Mucci et al. 2016). The purpose of this paper is two-fold. First, it describes the twin registers in the four countries participating in the Nordic Twin Study of Cancer (NorTwinCan) as a general reference for specific studies based on these registers. Second, it assesses whether the cancer mortality and incidence rates among individuals in the Nordic twin registers are similar to those in the general population.

While more than 2,000 articles have been published based on these four Nordic twin registers during the past 30 years [PubMed search November 2016], the features of cancer risk pattern among twins compared to the population have not been systematically analysed. For individual cancers, we have explored cancer risk among twins for prostate, breast, colorectal and lung cancer (Hjelmberg et al. 2014, 2016, Mucci et al. 2016). This paper, however, includes systematic descriptions of the participating twin registers: background, organisation, size, years of record collection, and administrative aspects that determine internal and external validity. We assessed whether twins have the same mortality profile as the general population to reveal possible selection issues of those included in the twin registers. Infant mortality rates are higher among twins than singletons (Farooqui et al. 1973; Keith 1994) but from childhood onwards, there is no reason to assume differential mortality between twins and non-twins (Christensen et al. 1995, Kaprio 2013).

To assess our a priori hypothesis that the rates of cancer mortality and cancer incidence among twins do not differ from those in the general population, we conducted comprehensive analyses of standardized mortality ratios (SMR) for overall mortality across country, age, period, follow-up years and of overall cancer and site-specific standardised incidence ratio (SIR) analyses across country, period, age, sex and zygosity.

Methods

Participating twin registers

The NorTwinCan network consists of twin registers in Denmark, Finland, Norway and Sweden (Table 1). These registers are independent research entities but committed to collaborative studies by working to harmonise policies for quality assurance, logistics and study designs as well as for permission and terms of collaboration. Since the mid-20th century, every citizen in the Nordic countries has been assigned an individually unique personal identity code (PIC), which is used in population registration and throughout the national health care systems. These codes enable complete follow-up through record linkage to ascertain vital status, addresses, health outcomes, migration and death. Research projects using the twin registers need appropriate permissions from both the national Data Protection Authorities, regional ethics committees and from the boards of the twin registers.

In all four of the Nordic twin registries zygosity classifications is based on questionnaire methodology relying on responses from the same-sexed twins to items about their similarity (Cederlöf et al. 1961; Sarna et al. 1978). This method classifies zygosity correctly in more than 95% of the same-sexed twin pairs when compared to zygosity determination based on genetic markers (Sarna et al. 1978, Christiansen et al. 2003, Harris et al. 2006). Zygosity assessment by genetic markers has been used increasingly due to lower cost, and by 2016 zygosity has been defined by genetic markers for more than 10,000 thousand twin pairs.

Denmark

Established in 1954 the Danish Twin Registry is the oldest population based twin register covering twins born since 1870. The twin cohorts were ascertained in four waves using different methods as previously described in detail (Skytthe et al. 2002; Skytthe et al. 2011). At present approximately 175,000 twin individuals have been included in the entire twin registry, although the NorTwinCan study included a subset. Vital status and emigration status are obtained through yearly linkage to the national civil registration system. In the current study twin pairs with both twins alive on January 1, 1943 or born thereafter are included.

Finland

The Finnish Twin Cohort Study was initiated in the early 1970s. Twins were ascertained in 1974 based on selection from Central Population Register of all pairs of persons born on the same date, of the same sex, in the same parish, and with the same surname at birth. The selection was restricted to persons born before 1958. A questionnaire was mailed to all potential twins aged 18 years or more in pairs with both twins alive in 1975 identifying more than 16000 like-sexed twin pairs, of which zygosity was known at baseline for 13,888, based on responses to questionnaires mailed in 1975. Not all pairs could be classified reliably as MZ or DZ, so twins of unknown zygosity may be due to this or to lack of response (Sarna et al, 1978). Persons who were not biological twins but satisfied the selection criteria were excluded based on the questionnaire response or after inquiries to local parishes as previously described in detail (Kaprio et al. 1978; Kaprio & Koskenvuo 2002). The Finnish Twin Cohort has been repeatedly linked with the Central Population Register to obtain data on death and emigration. In this study only same-sex twin pairs born 1890-1957 are included. In the late 1990s, the twin cohort was expanded to include also opposite-sex twins born between 1940 and 1957, however comprehensive inclusion of opposite-sex pairs was possible for pairs born 1950-1957 only.

Norway

The Norwegian Twin Registry was established in 2009, as a merger of three Twin Panels, covering respectively birth years 1895-1945, 1915-1960 and 1967-1979 as described in detail elsewhere (Bergen, 2002; Harris et al. 2002; Harris et al. 2006; Nilsen et al. 2012). Twins born before 1960 had to be alive in 1960 for assignment of national PIC introduced in 1964, based on the 1960 national census. Twins born after 1967 were registered in the medical birth registry, complete from 1967 onwards. The registry has information on 48,008 twins, of whom 31,362 have provided consent. As linkage to Norwegian registers including the Cancer Registry requires consent from twins, twin pairs where one or both twins are non-consenting twins have been excluded in this study. Data from the Norwegian Twin Registry have been matched with information from the National Cause of Death Registry (with complete data in electronic format from 1951 onwards).

Sweden

Compiled in several waves, the initial Swedish twin cohort was comprised of twins born 1886-1925 who were identified by investigators beginning in the 1960s from local parish registers. In 1961, a questionnaire was sent to all same-sexed twin pairs with both twins alive and living in Sweden. If both twins in a pair responded the twin pair was included in the register. Information about opposite-sexed twin pairs from these cohorts was added subsequently in late 1990s. Twins born 1926-1958 were identified in 1970 from national birth registers, and a questionnaire was sent to all pairs alive and living in Sweden 1973. Younger twin cohorts have only recently been contacted as part of different studies, in which zygosity was assessed for same-sex twins (Magnusson et al. 2013). Data on death and emigration have been obtained on regular basis through linkage to the population register and the Swedish Mortality Register.

Study sample

For the comparisons of standard incidence and mortality ratios, we restricted these analyses to same-sexed twins for several reasons. First, only opposite-sexed twins born 1950-1957 would be comprehensively available from Finland. Second, no opposite-sexed twins from the birth cohorts 1911-1930 are registered in the Danish Twin Registry. Third, only deceased opposite-sexed twins from Norway were present from birth cohorts before 1960, and among younger birth cohorts opposite-sexed twins were included during 1967 to 1976. Fourth, the Swedish opposite-sexed twins born before 1926 were incompletely represented. Opposite-sex pairs studied by Ahrenfeldt et al. 2016, showed no evidence for differences in cancer risk between OSDZ and SSDZ pairs.

Cancer incidence

The twin data were linked to the national cancer registries in each country to identify twins with one or more cancer diagnoses since enrolment in the twin register. The linkages were conducted in 2011-2012 when cancer registration was complete through 2010 for Finland, 2009 for Denmark and Sweden, and 2008 for Norway. Updated linkages currently underway will substantially increase the number of cancer cases. The Danish Cancer Registry holds information on tumours diagnosed since 1943, the Finnish and Norwegian Cancer Registries

since 1953, and the Swedish Cancer Registry since 1958 (Pukkala et al. 2018). Cancer registration is virtually complete with more than 98% of all known tumours included in the register in Denmark (, Finland and Norway. In Sweden, cancer cases are not traced via information in death certificates which has caused incompleteness of about 4% of all cancer sites and a much higher percentage of incompleteness of some cancer types with short survival (Mattsson, 1984).

Follow-up

The twin registers are also followed for vital status and emigration through national registers in each country on causes of death and the central population registers for vital status. To calculate person-years at risk of death and incident cancer, follow-up started at various dates depending on the methods of ascertainment in each of the four cohorts (Supplemental Table S1). Follow-up ended at death, at date of emigration, or at the common closing date of follow up (31 December 2008 for Norway and Sweden, 31 December 2009 for Denmark, and 31 December 2010 for Finland).

Statistical methods

To assess whether mortality and cancer incidence in the population-based twin cohorts is representative of their respective background populations, the numbers of observed deaths, cancer cases and person-years at risk were counted for five-year calendar periods, by sex, and five-year age groupings.

The standardized mortality ratio (SMR) for overall mortality was defined as the ratio of the observed to expected number of deaths. The expected numbers of deaths were calculated by multiplying the number of person-years in each stratum by the corresponding reference mortality rate downloaded from the Human Mortality Database (www.mortality.org).

Due to different cancer coding schemes in the four national cancer registers, we used the NORDCAN grouping of cancer diagnoses into 40 cancer sites to compare incidences across the four countries over time (Engholm et al. 2010).

The standardized incidence ratio (SIR) was defined as the ratio of the observed to expected number of cancer cases. The expected numbers of cases for total cancer and for the specific cancer types were calculated by multiplying the number of person-years in each stratum by

the corresponding cancer incidence rate in the national population was obtained from the NORDCAN database. The NORDCAN database incidences are not adjusted for competing risk of death from other causes and hence underestimates the true incidence in each stratum. Analyses adjusting for competing risks of death have been implemented in other papers from NorTwinCan. For the 95% confidence intervals (CI) of the SMR and SIR estimates it was assumed that the number of observed cases followed a Poisson distribution.

Results

More than 260,000 persons from same-sexed twin pairs in the Nordic twin registers were included and the accumulated number of person-years was 6.65 million (Table 1). The mean length of follow-up was 25.5 years. Zygosity was known for 78% of twin pairs; the main reason for missing data were the unavailability of the twins (deaths or missing address data) or lack of response to questionnaires. Of those with known zygosity, 39% were monozygous twins. The birth year distribution of the twins in each national twin cohort is described in Supplemental Figure S1.

Overall mortality

The SMR during a twin's first year of life was 4.44 (95% CI 4.23-4.67), reflecting the high-risk nature of twin pregnancies. The SMRs estimates, excluding the first year of life, were between 0.93 and 0.99 in all countries (Table 2). The SMR for all countries combined varied from 0.89 in monozygotic twins to 1.28 in the twins with unknown zygosity (Table 3), with similar results in each of the four countries. The higher SMRs in twins with unknown zygosity reflects the higher rates of substance use, smoking and psychiatric problems among non-responders to health surveys.

Supplemental Figure S2 shows the distributions for SMR by age, birth year, period, and follow up time. Danish twins had a mortality similar to the general population during the whole period. The age pattern shows only minor deviations from the expected values of SMR, and this also applies to the birth cohort pattern.

Mortality in the Finnish twin cohort is also similar to the general population except for a slightly lower mortality in the beginning of the period. This pattern is found in all cohorts, especially among twins with known zygosity (Supplemental Figure S3). The longer the time

since follow-up began the closer the SMR comes to 1 indicating that left-truncation or the selection of both twins in a pair being alive at initiation of follow-up may entail oversampling of individuals with a lower mortality rate.

Mortality is lower among the Swedish twin cohorts by age, birth year and period for most twin categories, especially for the twins with known zygosity.

The mortality pattern deviates more from that in the general population in the Norwegian and Swedish than in the other Nordic twin cohorts. The SMR values among the older Norwegian twins are close to 1, but are increasingly lower for the younger cohorts. Low SMR estimates are also observed in the beginning of the period most likely due to the “healthy worker effect” when both twins in a pair had to be alive for ascertainment at a specific date. Cohorts born before 1945 and with unknown zygosity are poorly represented in the data set; cohorts born between 1920 and 1945 with unknown zygosity do indeed only include twins that have died. Also, left-truncation or the selection of both twins in a pair being alive at initiation of follow-up may be influential.

Cancer incidence

The number of cancer cases diagnosed in the study period exceeds 30,000. The observed numbers - excluding non-melanoma skin cancer - among both men and women in all twin registers were slightly lower than those expected based on the national cancer incidence rates, yielding SIRs 0.97; (95% CI 0.96-0.99) in men and 0.96; (95% CI 0.94-0.97) in women (Table 4). The SIR estimates were below 1.0 in all countries for both sexes, except among Finnish and Norwegian men where the estimated SIR was 1.01 and 1.02, respectively and not significantly different from unity. Overall cancer incidence was similar for men and women in three of the four countries; the exception was Norway, where a marked difference was observed for the women (SIR 0.92; 0.87-0.96). The overall SIR for cancer incidence was similar for monozygotic (MZ) and dizygotic (DZ) twins in each country (Table 5).

The SIR estimates for the majority of site-specific cancers were not significantly different from 1.00 (Table 6). Only male lip, prostate, and testis cancer showed significantly, albeit slightly, higher estimates of SIR than 1.00, while no sites among women showed significantly elevated estimates. Among men and women, three and seven of 40 sites, respectively showed SIR estimates significantly lower than one. No adjustment for multiple testing is made here, but 13 of the 80 comparisons are significant at the $p < 0.05$ level, compared to 4 expected.

Among the major cancer sites with at least 100 cases, the lowest SIR estimates in both sexes were observed for kidney cancer, with SIRs of 0.82 in men and 0.83 in women (Table 6). Significantly lower SIR estimates were also seen for colon cancer, SIR values were 0.90 for men and 0.87 for women, and for lung cancer 0.88 and 0.95, respectively. Differences emerged when comparing the twin cohorts from each country, especially among men (data not shown). SIR estimates were significantly greater than 1.0 among the Norwegian men for cancer of the pharynx, stomach, larynx, testis, and bone, but none were below 1.0 in this group.

No difference in SIR estimates is found for cancer in general between twins with known zygosity and twins with unknown zygosity – both groups have SIR estimates just below 1. But differences do emerge for site-specific cancers (Table 7). The most striking differences are found for lung cancer, where the SIR estimate for twins with known zygosity is 0.86 (95% CI 0.82-0.89) and 1.13 (95% CI 1.02-1.26) for twins with unknown zygosity probably due to non-responders being more likely to be smokers, and for prostate cancer the SIR estimates were 1.06 (1.02-1.09) and 0.85 (0.76-0.95) respectively. This may reflect higher SES status among participants in the twin surveys, and higher likelihood to undergo prostate cancer screening in Norway, Sweden and Finland.

For same-sexed twins with known zygosity the site-specific SIR estimates for the MZ and the DZ twins are generally close to each other (Table 7). For 20 of the 40 sites investigated, the SIR point estimate is greater among the MZ than the DZ twins, and this difference is most pronounced for the prostate and testis cancer (prostate: 1.11 (95% CI 1.05-1.17) and 1.03 (95% CI 0.99-1.08) for MZ and DZ, respectively; and for testis the values are 1.36 (95% CI 1.12-1.65) and 1.08 (95% CI 0.91-1.28) for MZ and DZ, respectively. Other notable sites where MZ values were significantly lower than DZ values include colon, pancreas, and lung. In contrast, there were no zygosity differences in the SIR estimates for kidney cancer which were significantly lower among both MZ and DZ twins.

Discussion

This study reports on mortality and cancer incidence in twin cohorts from four Nordic countries with a long tradition of population-based research based on national registers. The data comprise information on more than 260,000 twins and enable research into genetic influences on the liability to develop specific types of cancer beyond what has previously

been possible. Further, the twin design allows studies of environmental causes of cancer while accounting for background genetic and familial influences.

The Nordic twin registers are regularly linked with national population registers to update information on death. Follow-up for emigration has not always been considered important in these studies because its magnitude has remained small but when the follow-up times increase the dates of emigration as an end-of-follow-up event should also be systematically linked to these twin registers. Even a small proportion of never-dying persons will bias the SMR and SIR estimates markedly downward (Pukkala, 2011). Therefore, it is important to link every research cohort with the population registry before follow-up studies to confirm that every person in the cohort really exists in the population either alive or with date of emigration or death.

The overall mortality rates are 1-5% lower in all four countries among individuals in the Nordic twin cohorts than in the general population. These differences can be explained by specific periods and/or birth cohorts, for which the ascertainment or the follow-up had shortcomings. For example, the Danish twins born from 1953-1982 are identified based on information from the population register regarding the relationship between parents and children. However, for the birth cohorts 1953-1960 this information is incomplete and 10-40% of the twin pairs born in this period are not included in the register (Skytthe et al. 2002). Likewise, the establishment of the early part of the register in Finland and Sweden, was based on the identification of complete twin pairs with both twins alive to be included in surveys (Kaprio et al. 1978; Cederlöf et al. 1961). In Norway, twins must consent to be part of the NTR research program as a prerequisite for conducting linkages to the National Cancer Registry. If only one twin has consented then information from the pair will often be excluded from analyses. Still, the overall differences are fairly small, and unlikely to lead to meaningful differences.

In comparison to the general population, mortality is lower among twins with known zygosity and significantly higher among twins with unknown zygosity. This most likely reflects bias in survey response, which is how zygosity status was determined. Those who participate in health surveys tend to have better mental and physical health and a healthier lifestyle than non-participants (Nohr et al (2018), Silva et al (2015), Ellenberg (1994)). Notably, smokers are less likely to participate in surveys, and this is seen in the SIR differences for lung cancer between twin pairs of known and unknown zygosity. In these cohorts, smoking was,

expectedly, a strong predictor of lung cancer incidence (Hjelmberg et al. 2017). This bias is reflected in a higher risk of premature death and increased risk of cancers that are strongly associated with lifestyle factors such as tobacco and alcohol-related cancers.

The Nordic health data infrastructure and the unique personal identity codes are utilised in all important registers to allow electronic linkages of numerous register-based health indicators. Data from many other registries may indeed be used as outcome variables or as co-factors for in controlling potential confounding. Hospital discharge registries, perinatal outcome registries, cause of death registries, registries of infectious diseases and various disease-specific registries (diabetes, AIDS, etc), registers of prescribed medications, disability pensions and other administrative registers with health-relevant data are commonly used (Christensen et al. 2011; Pukkala, 2011). The Nordic cancer registries are also able to produce data for non-standard categories based on variables such as morphology and spreading, and for certain precancerous lesions (Pukkala et al. 2018).

The pattern of incidence across cancer types in the twins tends to reflect that of the general population. The overall cancer risk was marginally lower than average across most of the twin cohorts. Again, this is most likely due to the response bias whereby participation rates are better among healthier and-conscientious subjects. Assessment of zygosity also depends on survey participation and hence is a source of potential selection bias. The SIRs varied systematically between the groups of twins with known versus unknown zygosity, with higher rates among the group with known zygosity for cancers associated with high SES and better lifestyle and higher rates among the group with unknown zygosity for cancers associated with low SES and more smoking and alcohol use. However, the SIR based on data from all the twins combined (those with and without zygosity determination) indicates that twins are highly representative of the population overall. The few sites where the twin SIR deviate unexpectedly from the population values require further study; for example, there is no obvious reason why kidney cancer should be much less common among twins than singletons.

Our study illustrates multiple advantages of combining the twin cohorts in the Nordic countries. The increased number of cases facilitates studies of rare cancers that could not be conducted based on the data from single countries. Analyses based on greater sample sizes yield more precise estimates of familial risk, heritability and the influence of environmental factors on cancer liability (Mucci et al. 2016). Increasing the number of monozygotic twin

pairs in which only one of the twins has a rare cancer permits studies of environmental factors independent of the genetic liability to disease. Such pairs are also extremely valuable for epigenetic studies. The long history of similar surveys among twins in the four countries facilitate the combination of data from different national surveys to study gene-environment interaction as exemplified by a recent study on genetic predisposition to smoking and lung cancer (Hjelmberg et al. 2016). Finally, the social and demographic structure in the four countries is similar, and a reliable and complete registration of a number of health events and conditions is common in the Nordic countries.

Conclusions

With an annual increase of about 1,600 cancer cases in the twin cohorts defined in this study, we estimate after our next linkage to cancer registries with information through 2017 more than 40,000 cancer cases will be available for further studies of cancer. The high internal validity of comparisons within a defined twin register cohort make prospective twin register-based study designs preferable for etiological studies. Overall, the population-representativeness is excellent, with only a slightly more favourable SMR and SIR profile than in the general population. This small deviation from the population values implies that generalization of results to entire national populations should be made with some caution. Because the Nordic twin registers are committed to work towards joint Quality Assurance standards, including defined accessibility to external research data requests, and as the twin registers together contain a huge number of prospectively occurring cases of cancer, the NorTwinCan twin register cohorts provide a solid basis for prospective studies on cancer causes and control as well as opportunities to explore factors that influence cancer using multiple study designs made possible with twin data (Boomsma et al, 2002).

Acknowledgements

Initial funding to NorTwinCan was provided by the Ellison Foundation. Several network researchers – in addition to those listed as authors – provided valuable comments in topics related to this study discussed in numerous joint network meetings. This study was supported by the Academy of Finland (grants 265240, 263278 to J Kaprio) and Nordic Cancer Union grants awarded in 2011 to J Kaprio, and in 2016 and 2017 to J R Harris. The Danish Twin

Cohort was supported by the Odense University Hospital AgeCare program of the Academy of Geriatric Cancer Research.

Additional contributions: We are grateful to the participants of the twin registries in Denmark, Finland, Norway, and Sweden.

References

- Ahrenfeldt, L. J., Skytthe, A., Möller, S., Czene, K., Adami, H. O., Mucci, L. A., Kaprio, J., Petersen, I., Christensen, K., Lindahl-Jacobsen, R. (2015). [Risk of Sex-Specific Cancers in Opposite-Sex and Same-Sex Twins in Denmark and Sweden](#). *Cancer Epidemiology, Biomarkers & Prevention*, 24, 1622-1628.
- Bergem, A. L. (2002). Norwegian Twin Registers and Norwegian twin studies – an overview. *Twin Research*, 5, 407-414.
- Boomsma, D., Busjahn, A., Peltonen, L. (2002). Classical twin studies and beyond. *Nature Reviews Genetics*, 3, 872-882
- Cederlöf, R., Friberg, L., Jonsson, E., Kaij, L. (1961). Studies on similarity diagnosis in twins with the aid of mailed questionnaires. *Acta Genetica et Statistica Medica*, 11, 338-362.
- Christensen, K., Kyvik, K. O., Holm, N. V., Skytthe, A. (2011). Register-based research on twins. *Scandinavian Journal of Public Health*, 39(Supp 7), 185-190.
- Christiansen, L., Frederiksen, H., Schousboe, K., Skytthe, A., von Wurmb-Schwark, N., Christensen, K., Kyvik, K. O. (2003). Age- and Sex-differences in the Validity of Questionnaire-based Zygosity in Twins. *Twin Research*, 6, 275-278.
- Engholm, G., Ferlay, J., Christensen, N., Bray, F., Gjerstorff, M. L., Klint, A., Køtlum, J. E., Olafsdóttir, E., Pukkala, E., Storm, H. H. (2010). NORDCAN - a Nordic tool for cancer information, planning, quality control and research. *Acta Oncologica*, 49, 725-736.
- Ellenberg JH. (1994). Selection bias in observational and experimental studies. Review. *Stat Med*. 13(5-7),557-567.
- Farooqui, M. O., Grossman, J. H. 3rd, Shannon, R. A. (1973). A review of twin pregnancy and perinatal mortality. *Obstetrical & Gynecological Survey*, 28(suppl), 144-153.
- Harris, J. R., Magnus, P., Tambs, K. (2002). The Norwegian Institute of Public Health Twin Panel: a description of the sample and program of research. *Twin Research*, 5, 415-423.
- Harris, J. R., Magnus, P., Tambs, K. (2006). The Norwegian Institute of Public Health twin program of research: an update. *Twin Research and Human Genetics*, 9, 858-864.
- Hjelmberg JB, Scheike T, Holst K, et al. (2014). The heritability of prostate cancer in the Nordic Twin Study of Cancer. *Cancer Epidemiol Biomarkers Prev*, 23, 2303–2310.
- Hjelmberg, J., Korhonen, T., Holst, K., Skytthe, A., Pukkala, E., Kutschke, J., Harris, J. R., Mucci, L. A., Christensen, K., Czene, K., Adami, H. O., Scheike, T., Kaprio, J. (2017). Lung cancer, genetic predisposition and smoking: the Nordic Twin Study of Cancer. *Thorax*, 72 (11), 1021-1027.

- Kaprio, J. (2013). The Finnish Twin Cohort Study: An Update. *Twin Research and Human Genetics*, 16, 157-162.
- Kaprio, J., Koskenvuo, M. (2002). Genetic and environmental factors in complex diseases: the older Finnish Twin Cohort. *Twin Research*, 5, 358-365
- Kaprio, J., Sarna, S., Koskenvuo, M., Rantasalo, I. (1978). The Finnish Twin Registry: formation and compilation, questionnaire study, zygosity determination procedures, and research program. *Progress in Clinical and Biological Research*, 24, 179-184.
- Keith, L. (1994). Mortality and morbidity among twins: recent observations from the United States. *Acta Genet Med Gemellol (Roma)*, 43, 25-31.
- Magnus, P., Berg, K., Nance, W. E. (1983). Predicting zygosity in Norwegian twin pairs born 1915-1960. *Clinical Genetics*, 24, 103-112.
- Magnusson, P. K., Almqvist, C., Rahman, I., Ganna, A., Viktorin, A., Walum, H., Halldner, L., Lundström, S., Ullén, F., Långström, N., Larsson, H., Nyman, A., Gumpert, C. H., Råstam, M., Anckarsäter, H., Cnattingius, S., Johannesson, M., Ingelsson, E., Klareskog, L., de Faire, U., Pedersen, N. L., Lichtenstein, P. (2013). The Swedish Twin Registry: establishment of a biobank and other recent developments. *Twin Research and Human Genetics*, 16, 317-29.
- Mattsson, B., Wallgren, A. (1984). Completeness of the Swedish cancer register. Non-notified cancer cases recorded on death certificates in 1978. *Acta Radiologica. Oncology*, 23, 305-313.
- Mucci, L. A., Hjelmborg, J. B., Harris, J., Czene, K., Havelick, D. J., Scheike, T., Graff, R. E., Holst, K., Möller, S., Unger, R. H., McIntosh, C., Nutall, E., Brandt, I., Penny, K. L., Hartman, M., Kraft, P., Parmigiani, G., Christensen, K., Koskenvuo, M., Holm, N. V., Heikkilä, K., Pukkala, E., Skytthe, A., Adami, H. O., Kaprio, J. (2016). Familial Risk and Heritability of Cancer Among Twins in Nordic Countries. *JAMA*, 315, 68-76.
- Nilsen, T. S., Brandt, I., Magnus, P., Harris, J. R. (2012). The Norwegian Twin Registry. *Twin Research and Human Genetics*, 15, 775-780.
- Nohr EA, Liew Z. (2018). How to investigate and adjust for selection bias in cohort studies. *Acta Obstet Gynecol Scand*. 97(4), 407-416.
- Pedersen, N. L., Lichtenstein, P., Svedberg, P. (2002). The Swedish Twin Registry in the Third Millenium. *Twin Research*, 5, 427-432.
- Pukkala, E. (2011). Biobanks and registers in epidemiological research on cancer. In: Dillner J (ed.) *Methods in Biobanking. Methods in Molecular Biology*, 2011, Vol 675. Totowa, Humana Press 2011, pp. 127-164.
- Pukkala, E. (1995). Cancer risk by social class and occupation. A survey of 109,000 cancer cases among Finns of working age. *Contributions to Epidemiology and Biostatistics*. Basel: Karger 1995;7.
- Pukkala, E., Engholm, G., Højsgaard Schmidt, L.K., Storm, H., Khan, S., Lambe, M., Pettersson, D., Ólafsdóttir, E., Tryggvadóttir, L., Hakanen, T., Malila, N., Virtanen, A., Johannesen, T.B.,

- Larønningen, S., Ursin, G. (2018). Nordic Cancer Registries – an overview of their procedures and data comparability. *Acta Oncologica*, 57, 440-455.
- Pukkala, E., Martinsen, J. I., Lynge, E., Gunnarsdottir, H. K., Sparén, P., Tryggvadottir, L., Weiderpass, E., Kjørheim, K. (2009). Occupation and cancer – follow-up of 15 million people in five Nordic Countries. *Acta Oncologica*, 48, 646-790.
- Sarna, S., Kaprio, J., Sistonen, P., Koskenvuo, M. (1978). Diagnosis of twin zygosity by mailed questionnaire. *Human Heredity*, 28, 241-254.
- Silva Junior SH, Santos SM, Coeli CM, Carvalho MS. (2015) Assessment of participation bias in cohort studies: systematic review and meta-regression analysis. *Cad Saude Publica*. 31(11), 2259-2274.
- Skytthe, A., Kyvik, K., Holm, N. V., Vaupel, J. W., Christensen, K. (2002). The Danish Twin Registry: 127 birth cohorts of twins. *Twin Research*, 5, 352-357.
- Skytthe, A., Kyvik, K. O., Holm, N. V., Christensen, K. (2011). The Danish Twin Registry. *Scandinavian Journal of Public Health*, 39(Supp 7), 75-78.

Table 1. Characteristics of the NorTwinCan cohort of twins from same-sexed twin pairs with follow-up for cancer incidence. MZ = Monozygotic twins, DZ = Dizygotic twins, UZ = Unknown zygosity

Country	Denmark	Finland	Norway	Sweden	Total
Birth cohorts	1870-2004	1880-1957	1895-1979	1886-2000	
N individual twins	92,108	28,184	25,804	114,652	260,748
N (%) MZ twins	24,786 (27)	7,712 (27)	10,690 (42)	37,121 (32)	80,309 (31)
N (%) DZ twins	43,534 (47)	16,949 (60)	12,993 (50)	49,906 (44)	123,382 (47)
N (%) UZ twins	23,788 (26)	3,523 (13)	2,121 (8)	27,625 (24)	57,057 (22)
N (%) female twins	44,618 (48)	13,991 (50)	13,436 (52)	58,559 (51)	130,604 (50)
First date of follow-up	Jan 1943	May 1976	Jan 1964	Jan 1962	
Median age at start of follow-up, years	4.6	32.3	31.3	29.2	24.4
End of follow-up	Dec 2009	Dec 2010	Dec 2008	Dec 2009	
Person years	2,886,920	838,218	602,621	2,322,556	6,650,315
Median follow-up time, years	35.7	34.7	27.8	19.1	28.3
N (%) Deaths	22,588 (25)	8,852 (31)	5,464 (21)	25,618 (22)	62,522 (24)
N incident cancer cases	9,885	4,582	3,436	12,308	30,211

Table 2. Observed (O) and expected (E) numbers of deaths, and standardised mortality ratios (SMR = O/E) with 95% confidence intervals (CI) among same-sexed twins in the Nordic twin registers, by country and sex. First year of life is excluded.

Country	Males				Females			
	O	E	SMR	95% CI	O	E	SMR	95% CI
Denmark	10,996	11,231	0.98	0.96-1.00	10,180	10,368	0.98	0.96-1.00
Finland	4,959	5,215	0.95	0.93-0.98	3,893	4,106	0.95	0.92-0.98
Norway	3,331	3,407	0.98	0.95-1.01	2,133	2,282	0.94	0.90-0.98
Sweden	12,469	13,308	0.94	0.92-0.95	13,000	13,492	0.96	0.95-0.98
All	31,755	33,161	0.96	0.95-0.97	29,206	30,248	0.97	0.95-0.98

Table 3. Observed (O) and expected (E) numbers of deaths, and standardised mortality ratios (SMR = O/E) with 95% confidence intervals (CI) among same-sexed twins in the Nordic twin registers, by zygosity. First year of life is excluded. MZ = Monozygotic twins, DZ = Dizygotic twins, UZ = Unknown zygosity

Zygosity	All countries			
	O	E	SMR	95% CI
MZ	18,108	20,385	0.89	0.88-0.90
DZ	34,331	36,420	0.95	0.94-0.96
UZ	8,422	6,604	1.28	1.25-1.30
All	60,961	63,409	0.96	0.95-0.97

Table 4. Observed (O) and expected (E) numbers of cancer cases (all sites but non-melanoma skin cancer), and standardised incidence ratios (SIR = O/E) with 95% confidence intervals (CI) among same-sexed twins in the Nordic twin registers, by country, and sex.

Country	Males				Females			
	O	E	SIR	95% CI	O	E	SIR	95% CI
Denmark	4,494	4,701	0.96	0.93-0.98	4,953	5,122	0.97	0.94-0.99
Finland	2,351	2,325	1.01	0.97-1.05	2,119	2,179	0.97	0.93-1.01
Norway	1,787	1,755	1.02	0.97-1.07	1,509	1,645	0.92	0.87-0.96
Sweden	5,626	5,906	0.95	0.93-0.98	6,204	6,508	0.95	0.93-0.98
All	14,258	14,687	0.97	0.96-0.99	14,785	15,454	0.96	0.94-0.97

Table 5. Observed (O) and expected (E) numbers of cancer cases (all sites but non-melanoma skin cancer), and standardised incidence ratios (SIR = O/E) with 95% confidence intervals (CI) among same-sexed twins in the Nordic twin registers, by country, and zygosity.

Country	MZ				DZ				UZ			
	O	E	SIR	95% CI	O	E	SIR	95% CI	O	E	SIR	95% CI
Denmark	2,924	3,067	0.95	0.92-0.99	5,575	5,772	0.97	0.94-0.99	948	984	0.96	0.90-1.03
Finland	1,266	1,236	1.02	0.97-1.08	2,686	2,719	0.99	0.95-1.03	518	550	0.94	0.86-1.03
Norway	1,170	1,199	0.98	0.92-1.03	1,520	1,619	0.94	0.89-0.99	606	582	1.04	0.96-1.13
Sweden	4,069	4,237	0.96	0.93-0.99	6,875	7,234	0.95	0.93-0.97	886	943	0.94	0.88-1.00
All	9,429	9,739	0.97	0.95-0.99	16,656	17,344	0.96	0.95-0.98	2,958	3,058	0.97	0.93-1.00

Table 6. Observed (O) and expected (E) numbers of cancer cases diagnosed by end of follow up among same-sexed twins in the Nordic twin registers, –by sex. Expected numbers based on national population; standardised incidence ratios (SIR = O/E) with 95% confidence intervals (CI).

Cancer site (ICD O-10 code)	Males				Females			
	O	E	SIR	95% CI	O	E	SIR	95% CI
1. Lip (C00)	148	125	1.18	1.01-1.39	22	30	0.72	0.48-1.10
2. Tongue (C01-02)	55	65	0.85	0.65-1.10	35	41	0.85	0.61-1.19
3. Mouth (C03-06+C46.2)	29	36	0.80	0.55-1.15	39	37	1.06	0.77-1.45
4. Salivary glands (C07-08)	83	90	0.92	0.74-1.14	67	62	1.06	0.85-1.37
5. Pharynx (C09-14)	140	130	1.07	0.91-1.27	45	49	0.93	0.69-1.24
6. Oesophagus (C15)	206	208	0.99	0.87-1.14	107	93	1.16	0.96-1.40
7. Stomach (C16)	736	713	1.03	0.96-1.11	475	486	0.98	0.89-1.07
8. Small intestine (C17)	52	63	0.82	0.63-1.08	52	58	0.90	0.68-1.18
9. Colon (C18)	971	1,054	0.92	0.87-0.98	1,100	1,238	0.89	0.84-0.94
10. Rectum and anus (C19-21)	801	811	0.99	0.92-1.06	601	667	0.90	0.83-0.98
11. Liver (C22)	214	211	1.02	0.89-1.16	156	146	1.07	0.92-1.25
12. Gallbladder and extrahepatic bile ducts (C23-24)	98	111	0.88	0.73-1.08	243	225	1.08	0.95-1.22
13. Pancreas (C25)	418	451	0.93	0.84-1.02	439	453	0.97	0.88-1.06
14. Nose, sinuses (C30-31)	46	36	1.27	0.95-1.70	22	24	0.92	0.61-1.40
15. Larynx (C32)	166	183	0.91	0.78-1.05	34	31	1.09	0.78-1.52
16. Lung (incl. trachea and bronchus) (C33-34)	1,739	2,000	0.87	0.83-0.91	924	1005	0.92	0.86-0.98
17. Pleura (C38.4+C45.0)	55	67	0.82	0.63-1.07	12	17	0.69	0.39-1.21
18. Breast (C50)	18	25	0.73	0.46-1.16	4,295	4,273	1.01	0.98-1.04
19. Cervix uteri (C53)					614	653	0.94	0.87-1.02
20. Corpus uteri (C54)					851	923	0.92	0.86-0.99
21. Uterus. other (C55+C58)					66	65	1.01	0.80-1.29
22. Ovary and uterine adnexa (C56,C57.0-4)					768	813	0.94	0.88-1.01
23. Other female genital organs (C51-52,C57.7-9)					148	148	1.00	0.85-1.17
24. Prostate (C61)	3,556	3,442	1.03	1.00-1.07				
25. Testis (C62)	253	220	1.15	1.02-1.30				
26. Penis and other male genital organs (C60+C63)	50	53	0.94	0.72-1.25				

27. Kidney (C64)	375	456	0.82	0.74-0.91	274	332	0.83	0.73-0.93
28. Bladder, ureter, urethra (C65-68+D09.0+D41.4)	1,176	1,140	1.03	0.97-1.09	413	424	0.97	0.88-1.07
29. Melanoma of skin (C43)	478	509	0.94	0.86-1.03	565	576	0.98	0.90-1.07
30. Skin, non-melanoma (C44+C46.0)	654	692	0.95	0.88-1.02	514	534	0.96	0.88-1.05
31. Eye (C69)	57	45	1.28	0.99-1.66	49	43	1.15	0.87-1.52
32. Brain, central nervous system (C70-72+D32-33+D42-43)	429	450	0.95	0.87-1.05	549	540	1.02	0.94-1.11
33. Thyroid (C73)	65	71	0.92	0.72-1.17	170	197	0.86	0.74-1.00
34. Bone (C40-41)	35	37	0.94	0.67-1.31	25	29	0.85	0.58-1.26
35. Soft tissues (C49+C46.1)	103	98	1.06	0.87-1.28	90	89	1.01	0.82-1.24
36. Non-Hodgkin lymphoma (C82-85,C96)	456	466	0.98	0.89-1.07	365	408	0.89	0.81-0.99
37. Hodgkin lymphoma (C81)	84	97	0.87	0.70-1.07	52	67	0.78	0.59-1.02
38. Multiple myeloma (C90)	196	192	1.02	0.89-1.17	140	170	0.82	0.70-0.97
39. Acute leukaemia (C91.0+C92.0+C93.0+C94.0+C95.0)	124	146	0.85	0.71-1.02	122	133	0.92	0.77-1.10
40. Other leukaemia (C91-C95\C9X.0)	258	262	0.98	0.87-1.11	185	183	1.01	0.88-1.17
41. All sites but non-melanoma skin	14,258	14,687	0.97	0.96-0.99	14,785	15,454	0.96	0.94-0.97

Table 7. Observed (O) and expected (E) numbers of cancer cases diagnosed by end of follow up among same-sexed twins by zygosity in the Nordic twin registers. Expected numbers based on national population; standardised incidence ratios (SIR = O/E) with 95% confidence intervals (CI). MZ = Monozygotic twins, DZ = Dizygotic twins, UZ = Unknown zygosity.

Cancer site (ICD O-10 code)	MZ				DZ				UZ			
	O	E	SIR	95% CI	O	E	SIR	95% CI	O	E	SIR	95% CI
1. Lip (C00)	56	49	1.15	0.88-1.49	100	89	1.12	0.92-1.37	14	18	0.79	0.47-1.33
2. Tongue (C01-02)	26	34	0.77	0.52-1.13	54	61	0.88	0.68-1.15	10	11	0.89	0.48-1.66
3. Mouth (C03-06+C46.2)	27	24	1.14	0.79-1.67	38	42	0.90	0.66-1.24	3	7	0.40	0.13-1.24
4. Salivary glands (C07-08)	38	48	0.79	0.57-1.08	94	88	1.07	0.87-1.30	18	16	1.16	0.73-1.84
5. Pharynx (C09-14)	56	57	0.99	0.76-1.28	90	104	0.87	0.71-1.70	39	19	2.08	1.52-2.85
6. Oesophagus (C15)	87	95	0.92	0.75-1.14	184	174	1.06	0.92-1.22	42	32	1.32	0.98-1.79
7. Stomach (C16)	366	380	0.96	0.87-1.07	681	675	1.01	0.94-1.09	164	144	1.14	0.98-1.33
8. Small intestine (C17)	32	40	0.81	0.57-1.14	59	70	0.84	0.65-1.09	13	11	1.13	0.66-1.95
9. Colon (C18)	643	744	0.86	0.80-0.93	1,223	1,323	0.92	0.87-0.98	205	225	0.91	0.79-1.04
10. Rectum and anus (C19-21)	470	476	0.99	0.90-1.08	799	851	0.94	0.88-1.01	133	152	0.88	0.74-1.04
11. Liver (C22)	125	113	1.10	0.92-1.31	213	208	1.02	0.89-1.17	32	34	0.93	0.66-1.31
12. Gallbladder and extrahepatic bile ducts (C23-24)	112	109	1.03	0.86-1.24	190	197	0.96	0.84-1.11	39	30	1.29	0.94-1.76
13. Pancreas (C25)	244	287	0.85	0.75-0.96	520	523	0.99	0.91-1.08	93	93	1.00	0.81-1.22
14. Nose, sinuses (C30-31)	21	19	1.10	0.72-1.69	36	35	1.04	0.75-1.45	11	6	1.71	0.95-3.08
15. Larynx (C32)	57	67	0.86	0.66-1.11	115	125	0.92	0.77-1.11	28	23	1.21	0.84-1.75
16. Lung (incl. trachea and bronchus) (C33-34)	786	950	0.83	0.77-0.89	1,526	1,745	0.87	0.83-0.92	351	310	1.13	1.02-1.26
17. Pleura (C38.4+C45.0)	24	26	0.91	0.61-1.35	38	49	0.77	0.56-1.06	5	9	0.56	0.23-1.35
18. Breast (C50)	1,437	1,430	1.01	0.95-1.06	2,527	2,489	1.02	0.98-1.06	349	379	0.92	0.83-1.02
19. Cervix uteri (C53)	211	219	0.96	0.84-1.10	332	375	0.89	0.80-0.99	71	58	1.21	0.96-1.53
20. Corpus uteri (C54)	291	304	0.96	0.85-1.08	495	540	0.92	0.84-1.00	65	79	0.82	0.64-1.04
21. Uterus. other (C55+C58)	24	22	1.10	0.74-1.64	36	38	0.95	0.69-1.32	6	5	1.10	0.49-2.45
22. Ovary and uterine adnexa (C56,C57.0-4)	247	269	0.92	0.81-1.04	436	473	0.92	0.84-1.01	85	72	1.19	0.96-1.47
23. Other female genital organs (C51-52,C57.7-9)	47	49	0.96	0.72-1.28	86	86	1.00	0.81-1.23	15	13	1.12	0.68-1.86
24. Prostate (C61)	1,207	1,092	1.11	1.05-1.17	2,023	1,966	1.03	0.99-1.08	326	384	0.85	0.76-0.95
25. Testis (C62)	100	74	1.36	1.12-1.65	129	120	1.08	0.91-1.28	24	27	0.89	0.60-1.32
26. Penis and other male genital organs (C60+C63)	15	17	0.89	0.54-1.47	34	30	1.13	0.80-1.58	1	6	0.17	0.02-1.21
27. Kidney (C64)	207	250	0.83	0.72-0.95	379	456	0.83	0.75-0.92	63	81	0.77	0.60-0.99

28. Bladder, ureter, urethra (C65-68+D09.0+D41.4)	518	500	1.04	0.95-1.13	904	907	1.00	0.93-1.06	167	158	1.06	0.91-1.23
29. Melanoma of skin (C43)	365	363	1.00	0.91-1.11	599	615	0.97	0.90-1.05	79	105	0.75	0.60-0.93
30. Skin, non-melanoma (C44+C46.0)	428	400	1.07	0.97-1.18	643	706	0.91	0.84-0.98	97	120	0.81	0.66-0.98
31. Eye (C69)	34	28	1.23	0.88-1.72	64	49	1.30	1.02-1.66	8	10	0.77	0.39-1.54
32. Brain, central nervous system (C70-72+D32-33+D42-43)	345	320	1.08	0.97-1.20	532	560	0.95	0.87-1.03	101	109	0.93	0.77-1.13
33. Thyroid (C73)	85	90	0.95	0.77-1.17	135	152	0.89	0.75-1.05	15	26	0.58	0.35-0.96
34. Bone (C40-41)	20	21	0.94	0.61-1.46	35	36	0.97	0.70-1.35	5	9	0.54	0.22-1.29
35. Soft tissues (C49+C46.1)	59	60	0.98	0.76-1.27	110	106	1.04	0.86-1.25	24	21	1.15	0.77-1.72
36. Non-Hodgkin lymphoma (C82-85,C96)	256	280	0.91	0.81-1.03	477	504	0.95	0.87-1.04	88	90	0.98	0.79-1.20
37. Hodgkin lymphoma (C81)	57	53	1.07	0.82-1.38	69	97	0.76	0.60-0.96	10	20	0.50	0.27-0.94
38. Multiple myeloma (C90)	116	116	1.00	0.84-1.20	175	208	0.84	0.73-0.98	45	38	1.17	0.87-1.57
39. Acute leukaemia (C91.0+C92.0+C93.0+C94.0+C95.0)	77	86	0.90	0.72-1.12	139	151	0.92	0.78-1.09	30	42	0.72	0.51-1.03
40. Other leukaemia (C91-C95\C9X.0)	139	143	0.98	0.83-1.15	266	255	1.04	0.92-1.18	38	47	0.81	0.59-1.11
41. All sites but non-melanoma skin	9,429	9,739	0.97	0.95-0.99	16,656	17,344	0.96	0.95-0.98	2,958	3,058	0.97	0.93-1.00